Difference between revisions of "Bevacizumab-bvzr (Zirabev)"
Warner-admin (talk | contribs) m (Text replacement - "Category:Antibody medications" to "") |
Warner-admin (talk | contribs) m (Text replacement - "Adenocarcinoma of unknown primary" to "Carcinoma of unknown primary") |
||
Line 9: | Line 9: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
<div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | <div style="column-count:3;-moz-column-count:3;-webkit-column-count:3"> | ||
− | *[[ | + | *[[Carcinoma of unknown primary]] |
*[[Anaplastic glioma]] | *[[Anaplastic glioma]] | ||
*[[Breast cancer]] | *[[Breast cancer]] | ||
Line 47: | Line 47: | ||
[[Category:VEGFR inhibitors]] | [[Category:VEGFR inhibitors]] | ||
− | [[Category: | + | [[Category:Carcinoma of unknown primary medications]] |
[[Category:Anaplastic glioma medications]] | [[Category:Anaplastic glioma medications]] | ||
[[Category:Breast cancer medications]] | [[Category:Breast cancer medications]] |
Revision as of 00:55, 22 May 2021
Note: this is a biosimilar. The information below is reproduced from the Bevacizumab (Avastin) page, except for the details of FDA indication.
General information
Class/mechanism: Monoclonal antibody that inhibits angiogenesis by binding VEGF and preventing the interaction of VEGF with its receptors (Flt-1 and KDR) on the surface of endothelial cells.
Route: IV
Extravasation: neutral
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape,UpToDate (courtesy of Lexicomp), or the prescribing information.
Diseases for which it is used
- Carcinoma of unknown primary
- Anaplastic glioma
- Breast cancer
- Cervical cancer
- Cholangiocarcinoma
- Colon cancer
- Esophageal cancer
- Follicular lymphoma
- Glioblastoma
- Hepatocellular carcinoma
- Melanoma
- Mesothelioma
- Neuroendocrine tumor
- Non-small cell lung cancer
- Ovarian cancer
- Pancreatic NET
- Renal cell carcinoma
- Small cell lung cancer
- Soft tissue sarcoma
- Testicular cancer
- Endometrial cancer
- Vascular sarcoma
History of changes in FDA indication
- 6/28/2019: Approved
Also known as
- Brand name: Zirabev
- Drugs
- Intravenous medications
- Neutral
- Anti-VEGFR antibodies
- VEGFR inhibitors
- Carcinoma of unknown primary medications
- Anaplastic glioma medications
- Breast cancer medications
- Cervical cancer medications
- Cholangiocarcinoma medications
- Colon cancer medications
- Esophageal cancer medications
- Follicular lymphoma medications
- Glioblastoma medications
- Hepatocellular carcinoma medications
- Melanoma medications
- Mesothelioma medications
- Neuroendocrine tumor medications
- Non-small cell lung cancer medications
- Ovarian cancer medications
- Pancreatic NET medications
- Renal cell carcinoma medications
- Small cell lung cancer medications
- Soft tissue sarcoma medications
- Testicular cancer medications
- Endometrial cancer medications
- Vascular sarcoma medications
- FDA approved in 2019
- Biosimilars